Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors

Leon T. Van Den Broeke, C. David Pendleton, Crystal Mackall, Lee J. Helman, Jay A. Berzofsky

Research output: Contribution to journalArticle

Abstract

Fusion proteins created by chromosomal translocations in tumors can create neoantigenic determinants at the breakpoint, which are unique to the tumor cells but shared by the vast majority of tumors of that histologic type. If the fusion protein is responsible for the malignant transformation, its expression cannot be lost by the tumor to escape immune responses against this tumor antigen. Here, we identify such a fusion protein breakpoint epitope in the PAX-FKHR fusion protein created by the t(2;13) translocation present in 80% of cases of alveolar rhabdomyosarcoma, a highly aggressive pediatric soft-tissue sarcoma. We use autologous dendritic cells pulsed with the RS10 breakpoint fusion peptide to raise a human CTL line from a normal healthy HLA-B7 + blood donor specific for this peptide. These CTLs are CD8 + (CD4-CD56-) and restricted by HLA-B7. These human peptide-specific CTL lyse human HLA-BV+ rhabdomyosarcoma tumor cells. Therefore, the fusion protein is endogenously processed to produce this natural epitope presented by HLA-B7 and thus this peptide is a bone fide human tumor antigen. We also define a substitution that increases the affinity for HLA-B7 without loss of antigenicity. This epitope-enhanced peptide may serve as a candidate cancer vaccine for HLA-B7+ patients with alveolar rhabdomyosarcoma.

Original languageEnglish (US)
Pages (from-to)1818-1823
Number of pages6
JournalCancer Research
Volume66
Issue number3
DOIs
StatePublished - Feb 1 2006
Externally publishedYes

Fingerprint

HLA-B7 Antigen
Alveolar Rhabdomyosarcoma
Alveolar Epithelial Cells
Genetic Translocation
Epitopes
Peptides
Neoplasm Antigens
Neoplasms
Proteins
Tumor Escape
Cancer Vaccines
Rhabdomyosarcoma
Blood Donors
Sarcoma
Dendritic Cells
Pediatrics
Bone and Bones

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors. / Van Den Broeke, Leon T.; Pendleton, C. David; Mackall, Crystal; Helman, Lee J.; Berzofsky, Jay A.

In: Cancer Research, Vol. 66, No. 3, 01.02.2006, p. 1818-1823.

Research output: Contribution to journalArticle

@article{a2723398728e4993b815b4eac0e313b3,
title = "Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors",
abstract = "Fusion proteins created by chromosomal translocations in tumors can create neoantigenic determinants at the breakpoint, which are unique to the tumor cells but shared by the vast majority of tumors of that histologic type. If the fusion protein is responsible for the malignant transformation, its expression cannot be lost by the tumor to escape immune responses against this tumor antigen. Here, we identify such a fusion protein breakpoint epitope in the PAX-FKHR fusion protein created by the t(2;13) translocation present in 80{\%} of cases of alveolar rhabdomyosarcoma, a highly aggressive pediatric soft-tissue sarcoma. We use autologous dendritic cells pulsed with the RS10 breakpoint fusion peptide to raise a human CTL line from a normal healthy HLA-B7 + blood donor specific for this peptide. These CTLs are CD8 + (CD4-CD56-) and restricted by HLA-B7. These human peptide-specific CTL lyse human HLA-BV+ rhabdomyosarcoma tumor cells. Therefore, the fusion protein is endogenously processed to produce this natural epitope presented by HLA-B7 and thus this peptide is a bone fide human tumor antigen. We also define a substitution that increases the affinity for HLA-B7 without loss of antigenicity. This epitope-enhanced peptide may serve as a candidate cancer vaccine for HLA-B7+ patients with alveolar rhabdomyosarcoma.",
author = "{Van Den Broeke}, {Leon T.} and Pendleton, {C. David} and Crystal Mackall and Helman, {Lee J.} and Berzofsky, {Jay A.}",
year = "2006",
month = "2",
day = "1",
doi = "10.1158/0008-5472.CAN-05-2549",
language = "English (US)",
volume = "66",
pages = "1818--1823",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors

AU - Van Den Broeke, Leon T.

AU - Pendleton, C. David

AU - Mackall, Crystal

AU - Helman, Lee J.

AU - Berzofsky, Jay A.

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Fusion proteins created by chromosomal translocations in tumors can create neoantigenic determinants at the breakpoint, which are unique to the tumor cells but shared by the vast majority of tumors of that histologic type. If the fusion protein is responsible for the malignant transformation, its expression cannot be lost by the tumor to escape immune responses against this tumor antigen. Here, we identify such a fusion protein breakpoint epitope in the PAX-FKHR fusion protein created by the t(2;13) translocation present in 80% of cases of alveolar rhabdomyosarcoma, a highly aggressive pediatric soft-tissue sarcoma. We use autologous dendritic cells pulsed with the RS10 breakpoint fusion peptide to raise a human CTL line from a normal healthy HLA-B7 + blood donor specific for this peptide. These CTLs are CD8 + (CD4-CD56-) and restricted by HLA-B7. These human peptide-specific CTL lyse human HLA-BV+ rhabdomyosarcoma tumor cells. Therefore, the fusion protein is endogenously processed to produce this natural epitope presented by HLA-B7 and thus this peptide is a bone fide human tumor antigen. We also define a substitution that increases the affinity for HLA-B7 without loss of antigenicity. This epitope-enhanced peptide may serve as a candidate cancer vaccine for HLA-B7+ patients with alveolar rhabdomyosarcoma.

AB - Fusion proteins created by chromosomal translocations in tumors can create neoantigenic determinants at the breakpoint, which are unique to the tumor cells but shared by the vast majority of tumors of that histologic type. If the fusion protein is responsible for the malignant transformation, its expression cannot be lost by the tumor to escape immune responses against this tumor antigen. Here, we identify such a fusion protein breakpoint epitope in the PAX-FKHR fusion protein created by the t(2;13) translocation present in 80% of cases of alveolar rhabdomyosarcoma, a highly aggressive pediatric soft-tissue sarcoma. We use autologous dendritic cells pulsed with the RS10 breakpoint fusion peptide to raise a human CTL line from a normal healthy HLA-B7 + blood donor specific for this peptide. These CTLs are CD8 + (CD4-CD56-) and restricted by HLA-B7. These human peptide-specific CTL lyse human HLA-BV+ rhabdomyosarcoma tumor cells. Therefore, the fusion protein is endogenously processed to produce this natural epitope presented by HLA-B7 and thus this peptide is a bone fide human tumor antigen. We also define a substitution that increases the affinity for HLA-B7 without loss of antigenicity. This epitope-enhanced peptide may serve as a candidate cancer vaccine for HLA-B7+ patients with alveolar rhabdomyosarcoma.

UR - http://www.scopus.com/inward/record.url?scp=32944481739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944481739&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-2549

DO - 10.1158/0008-5472.CAN-05-2549

M3 - Article

VL - 66

SP - 1818

EP - 1823

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 3

ER -